Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 1/20 | 0.57 |
| ▸ | KDR | P35968 | 5/20 | 0.56 |
| ▸ | EGFR | P00533 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TNKS | O95271 | 1/20 | 0.40 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.40 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12620149 | 0.88 | SMN1; SMN2 (0.46) | PDGFRBKDREGFRALDH1A1HPGD | |
| SCHEMBL1369022 | 0.82 | ALDH1A1 (0.45) | PDGFRBKDREGFRALDH1A1HPGD | |
| SCHEMBL31108170 | 0.79 | PDGFRB (0.71) | PDGFRBKDREGFRALDH1A1HPGD | |
| SCHEMBL1367826 | 0.79 | PDGFRB (0.71) | PDGFRBKDREGFRALDH1A1HPGD | |
| SCHEMBL14871018 | 0.78 | PARP1 (0.47) | PDGFRBKDREGFRPARP1MAOB | |
| SCHEMBL30588970 | 0.72 | TYMS (0.61) | KDREGFRPARP1CHEK1GRIN2D | |
| SCHEMBL1367742 | 0.72 | TYMS (0.61) | KDREGFRPARP1CHEK1GRIN2D | |
| SCHEMBL13915414 | 0.71 | SMN1; SMN2 (0.46) | PDGFRBALDH1A1HPGDSMN1; SMN2ADORA2A | |
| SCHEMBL13539588 | 0.70 | POLB (0.47) | ALDH1A1HPGDSMN1; SMN2ADORA2AADORA1 | |
| SCHEMBL9891925 | 0.70 | GRIN2D (0.46) | ALDH1A1HPGDSMN1; SMN2NR2E3GRIN2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11091500-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2021-08-17 | — | — | US | disclosed |
| US-10676483-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2020-06-09 | — | — | US | disclosed |
| US-10654858-B2 | Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2020-05-19 | — | — | US | disclosed |
| US-10654858-B2 | Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2020-05-19 | — | — | US | disclosed |
| EP-2310014-B1 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF | UNIV HOLY GHOST DUQUESNE (US) | 2020-03-18 | — | — | EP | disclosed |
| US-20200017521-A1 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2020-01-16 | — | — | US | disclosed |
| US-10464944-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2019-11-05 | — | — | US | disclosed |
| US-10414777-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and method of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2019-09-17 | — | — | US | disclosed |
| US-20190211019-A1 | TRICYCLIC COMPOUNDS HAVING CYTOSTATIC AND/OR CYTOTOXIC ACTIVITY AND METHODS OF USE THEREOF | DUQUESNE UNIVERSITY OF THE HOLY GHOST | 2019-07-11 | — | — | US | disclosed |
| US-20190211019-A1 | TRICYCLIC COMPOUNDS HAVING CYTOSTATIC AND/OR CYTOTOXIC ACTIVITY AND METHODS OF USE THEREOF | DUQUESNE UNIVERSITY OF THE HOLY GHOST | 2019-07-11 | — | — | US | disclosed |
| US-20110288108-A1 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF | GANGJEE ALEEM (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110207757-A1 | Tricyclic Compounds Having Cytostatic and/or Cytoxic Activity and Methods of Use Thereof | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2011-08-25 | — | — | US | disclosed |
| US-20110207757-A1 | Tricyclic Compounds Having Cytostatic and/or Cytoxic Activity and Methods of Use Thereof | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2011-08-25 | — | — | US | disclosed |
| US-20110207757-A1 | Tricyclic Compounds Having Cytostatic and/or Cytoxic Activity and Methods of Use Thereof | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2011-08-25 | — | — | US | disclosed |
| US-7982035-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2011-07-19 | — | — | US | disclosed |
| US-7960400-B2 | Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960400-B2 | Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2011-06-14 | — | — | US | disclosed |
| US-20090082374-A1 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2009-03-26 | — | — | US | disclosed |
| US-20090062318-A1 | TRICYCLIC COMPOUNDS HAVING CYTOSTATIC AND/OR CYTOTOXIC ACTIVITY AND METHODS OF USE THEREOF | DUQUESNE UNIVERSITY OF THE HOLY GHOST | 2009-03-05 | — | — | US | disclosed |
| US-20090062318-A1 | TRICYCLIC COMPOUNDS HAVING CYTOSTATIC AND/OR CYTOTOXIC ACTIVITY AND METHODS OF USE THEREOF | DUQUESNE UNIVERSITY OF THE HOLY GHOST | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082374-A1 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF | ABCG2, ABCC1, ABCB1 | PDGFRB 4281/4885KDR 4107/4885EGFR 3072/4885 |
| US-20200017521-A1 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF | PLK1, AURKC, TOP1 | PDGFRB 4770/4885KDR 4822/4885EGFR 3430/4885 |
| US-20110288108-A1 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF | ABCG2, ABCC1, ABCB1 | PDGFRB 4281/4885KDR 4107/4885EGFR 3072/4885 |
| US-10676483-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | PLK1, AURKC, TOP1 | PDGFRB 4770/4885KDR 4822/4885EGFR 3430/4885 |
| US-20090062318-A1 | TRICYCLIC COMPOUNDS HAVING CYTOSTATIC AND/OR CYTOTOXIC ACTIVITY AND METHODS OF USE THEREOF | DHFR, TK1, TYMS | PDGFRB 586/4885KDR 46/4885EGFR 334/4885 |
| US-11091500-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | ABCC1, ABCB1, ABCG2 | PDGFRB 3869/4885KDR 4154/4885EGFR 2114/4885 |
| US-10464944-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | ABCC1, ABCG2, TP53 | PDGFRB 4450/4885KDR 4411/4885EGFR 3140/4885 |
| US-20190211019-A1 | TRICYCLIC COMPOUNDS HAVING CYTOSTATIC AND/OR CYTOTOXIC ACTIVITY AND METHODS OF USE THEREOF | DHFR, TK1, TYMS | PDGFRB 586/4885KDR 46/4885EGFR 334/4885 |
| US-10414777-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and method of use thereof | ABCG2, ABCC1, ABCB1 | PDGFRB 4264/4885KDR 4111/4885EGFR 3276/4885 |
| US-20110207757-A1 | Tricyclic Compounds Having Cytostatic and/or Cytoxic Activity and Methods of Use Thereof | DHFR, TK1, TK2 | PDGFRB 606/4885KDR 42/4885EGFR 327/4885 |
| US-10654858-B2 | Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof | DHFR, TK1, TYMS | PDGFRB 586/4885KDR 46/4885EGFR 334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.